The Society for Immunotherapy of Cancer 26th Annual Meeting
November 4-6, 2011
Bethesda North Marriott Hotel & Convention Center
North Bethesda, MD
Program Organizers
Charles G. Drake, MD, PhD – Johns Hopkins University
Dolores J. Schendel, PhD – Helmholtz Zentrum Muenchen – German Research Center for Environmental Health Institute of Molecular Immunology
Jeffrey Schlom, PhD – National Cancer Institute, National Institutes of Health
Jedd D. Wolchok, MD, PhD – Memorial Sloan-Kettering Cancer Center
Program Summary
The SITC Annual Meeting program format and content is designed to address identified needs/practice gaps and promotes:
- Exchange between basic and clinical researchers, thus improving the caliber of the science and promoting translation
- Discussion on potential hurdles in cancer immunotherapy from the trial design and regulatory perspective
- Integrated understanding of the state of cancer immunotherapy research in today’s environment, identification of potential funding opportunities, and mentoring of junior investigators
- Discussion of novel therapies and applications based on the research presented
- Interactions with industry to promote access to novel agents for clinical development
Target AudienceThe target audience for this program was basic and clinical investigators from academic institutions, industry and regulatory agencies, including clinicians, basic and translational researchers, graduate students, post-doctoral fellows, and allied health professionals involved in cancer research.
Presentations and video recordings are available based on permission from presenters.
#Biomarkers #ClinicalTrials #BrainCancers #BreastCancers #HematologicMalignancies #ProstateCancer #PresentationSlides #AnnualMeeting #CombinationTherapy #ImmuneCheckpointInhibitors #TherapeuticAntibodies #Vaccines #AlliedHealth #Clinician #Industry #Oncologist #Researcher #2011 #Melanoma #Leukemia #Lymphoma #Myeloma #RenalCellCarcinoma #AdoptiveCellTherapy #Cytokines